Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States.
Lisa HardingKruti JoshiMaryia ZhdanavaAditi ShahArthur VoegelCindy ChenDominic PilonPublished in: Drugs - real world outcomes (2024)
Patients generally required more time than label recommendation to complete esketamine induction treatment, and most went on to have 12 or more esketamine sessions. Completion of induction treatment correlated with reductions in mean all-cause and MH-related acute healthcare costs. Larger reductions were seen in the subgroup of prior acute healthcare users.
Keyphrases
- healthcare
- liver failure
- respiratory failure
- end stage renal disease
- drug induced
- chronic kidney disease
- randomized controlled trial
- combination therapy
- aortic dissection
- clinical trial
- prognostic factors
- physical activity
- health insurance
- study protocol
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- mechanical ventilation
- sleep quality
- patient reported